Table 2.
Summary of covariate values for patients in the population PK analysis dataset
| Covariate | Median (range) or categories (%) |
|---|---|
| Continuous | |
| Age (years) | 65 (23–91) |
| Serum albumin (g/L) | 39 (12–55) |
| Aspartate aminotransferase (U/L) | 22 (4–127) |
| Total bilirubin (µM) | 7 (1.71–39.3)a |
| BSA (m2) | 1.88 (1.23–2.67) |
| Creatinine clearanceb (mL/min) | 86.8 (25.8–297) |
| Hematocrit (proportion of 1) | 0.35 (0.15–0.54) |
| Hemoglobin (g/dL) | 11.6 (4.6–16.8) |
| Body weight (kg) | 75.5 (36.7–151) |
| Categorical | |
| Len/dex combination | |
| Single agent | 29.9 |
| Len/dex combination | 70.1 |
| Race | |
| White | 79.9 |
| Black | 5.56 |
| Asian | 11.7 |
| Other | 2.91 |
| Sex | |
| Female | 42.4 |
| Male | 57.6 |
| Smoking status | |
| Never | 33.1 |
| Current | 4.37 |
| Former | 18.5 |
| Unknown | 44.1 |
BSA body surface area, Len/dex lenalidomide-dexamethasone, PK pharmacokinetic
a0.4 (0.1–2.3) mg/dL
bCreatinine clearance estimated using the Cockcroft–Gault equation [33]